WATERTOWN, Mass--(BUSINESS WIRE)--Sep. 3, 2019--
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that senior management will present a corporate overview at the H. C. Wainwright and Company 21st Annual Global Investment Conference on Monday, September 9, 2019 at 2:35 p.m. ET at the Lotte New York Palace Hotel in New York City.
A live audio webcast of the H.C. Wainwright Global Investment Conference presentation will be available on the Company’s website at https://tphase.gcs-web.com/events-presentations. The archived presentation will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention. The Company has created more than 3,000 novel tetracycline compounds using its proprietary technology platform. Tetraphase's lead product XERAVA™ is approved for the treatment of complicated intra-abdominal infections by the U.S. Food and Drug Administration and the European Medicines Agency. The Company’s pipeline also includes antibiotics TP-271 and TP-6076, which are Phase 2 ready, and TP-2846, which is in preclinical testing for acute myeloid leukemia. The Company intends to out license its pipeline candidates. Please visit www.tphase.com for more company information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190903005017/en/
Source: Tetraphase Pharmaceuticals, Inc.